Benefit — independent verifier vs self-attest
Why independent-verifier beats self-attest in every review venue
Clinical-AI vendor self-attestation, CRO reports, and internal-audit reports are inputs to a review. An independent-verifier declaration is evidence that changes the venue's opening stance.
The evidentiary weight difference
| Venue | Vendor self-attest | CRO / internal audit | Independent verifier |
|---|
| FDA BIMO | Input; probed further | Input; probed further | Evidence; moves the frame |
| FDA Type B/C reviewer | Insufficient standing | Partial credit | Full credit |
| EMA scientific advice | Weak | Moderate | Strong |
| ICH E6(R3) essential-documents review | Not accepted as independent | Not independent | Independent by definition |
| DSMB pre-read | Opening frame unchanged | Opening frame unchanged | Opening frame rebutted |
| IRB continuing-review | Weak | Moderate | Strong |
| Diligence / partner licensing | Growing dismissal risk | Discount partial | Discount full |
Why the difference exists
- Structural independence. The verifier has no employment, contract, equity, or vendor relationship with the sponsor, clinical-AI vendor, CRO, or EDC/eTMF/CTMS vendor. No economic incentive to soften findings.
- Methodological independence. Distinct model family, distinct math, distinct retention pipeline. Not re-running production instrumentation with a different logo on it.
- Named principal accountability. A named person signs. Addressable. Cross-examinable. The declaration is not an anonymous corporate output.
- Bounded scope honesty. The declaration explicitly bounds what is covered and what is not. No false-positive comfort.
What venues actually score against
Every regulator, IRB, DSMB, court, and diligence partner applies some version of the same test: could a reasonable sponsor have known + acted, and can that reasonable diligence be documented independently? The independent-verifier declaration is the direct answer to that question.
Why "we use our clinical-AI vendor's monitoring" is the wrong answer
Vendor monitoring modules are optimized to make the vendor's own product look good. That is a structural property, not a criticism of any specific vendor. Reviewers, IRBs, plaintiff counsel, and diligence partners all know this. Presenting vendor self-attestation as the sponsor's evidence is the modal weak answer.
"The CTMS dashboard was green" is exactly the situation the sample Snapshot documents — while the operational failure ran silently for 45+ days. The dashboard was not lying. It was structurally blind to the failure mode.
Who at your org cares
- General Counsel — every follow-on review venue
- VP Regulatory Affairs — FDA + EMA + IRB stance
- Chief Quality Officer — sponsor QMS integrity
- Chief AI Officer / Data Science lead — program credibility
- CEO / Board Science Committee — oversight defensibility
$499. 3 business days.
Signed independent-verifier declaration on your sponsor's actual AI surface. Named principal. Retained evidence.
Buy $499